论文部分内容阅读
目的 探讨Ｂｃ１－２和Ｃ－ｍｙｃ在阴茎癌组织中的表达及其意义。方法应用免疫组化法（ＳＡＢＣ）对４９例阴茎癌 组织和９例正常阴茎组织标本进行ｂｃ１－２和 ｃ－ｍｙｃ蛋白产物检测。结果 ４９例阴茎癌标本中２６例ｂｅ１－２检测阳性 （５３．１％）：２５例ｃ－ｍｙｃ检测阳性（５１％），９例正常阴茎２例ｂｅ１－２检测阳性（２２．２％）；Ｃ－ｍｙｃ未见阳性染色。Ｂｅ１－２阳性率 在高、中、低分化肿瘤中分别为 ８３．３％、５５．６％、３１．６％。在临床Ⅰ／Ⅱ期和Ⅲ／Ⅳ期肿瘤中分别是６９％，３０％。 ｃ－ｍｙｃ阳性率在高、 中、低分化肿瘤中分别为２５％，５０％，６８．４％。在临床Ⅰ／Ⅱ期和Ⅲ／Ⅳ期肿瘤中分别为３４．５％，７５％。显示ｂｅ１－２表达阳性率与阴 茎癌的病理分级和临床分期呈负相关（Ｐ＜０．０５），而ｃ－ｍｙｃ阳性表达率与阴茎癌的病理分级和临床分期呈正相关（Ｐ＜０．０５）。 结论 ｂｅ１－２，ｃ－ｍｙｃ蛋白的表达与阴茎癌组织病理分级和临床分期密切相关，ｂｅ１－２和 ｃ－ｍｙｃ可以作为阴茎癌的瘤标。
Objective To investigate the expression of Bcl-2 and C-myc in penile cancer and its significance. Methods The expression of bc1-2 and c-myc in 49 cases of penile cancer tissues and 9 cases of normal penile tissues were detected by immunohistochemistry (SABC). Results Of the 49 cases of penile cancer, 26 cases were positive for be1-2 (53.1%), 25 cases were positive for c-myc (51%) and 2 cases were positive for be1-2 (22.2%) in 9 cases of normal penis. ; C-myc no positive staining. The positive rate of Be1-2 was 83.3%, 55.6% and 31.6% in high, moderate and poorly differentiated tumors respectively. In clinical stage I / II and III / IV tumors were 69%, 30%. The positive rate of c-myc was 25%, 50% and 68.4% in high, moderate and poorly differentiated tumors respectively. In clinical stage I / II and stage III / IV tumors were 34.5%, 75%. The positive rate of be1-2 expression was negatively correlated with the pathological grade and clinical stage of penile cancer (P <0.05), while the positive expression rate of c-myc was positively correlated with the pathological grade and clinical stage of penile cancer (P <0.05). 05). Conclusion The expression of be1-2 and c-myc proteins is closely related to the pathological grade and clinical stage of penile cancer tissues. Be1-2 and c-myc can be used as tumor markers of penile cancer.